Researchers used nanoparticle technology to encapsulate paclitaxel and target bladder tumors more effectively. Early results demonstrate tumor elimination and minimal side effects.
A new drug developed at UC Davis Health could provide a safer and more effective option for bladder cancer patients, reducing chemotherapy toxicity and potentially limiting the need for bladder removal surgery.
The therapy, known as PLZ4-coated paclitaxel-loaded micelles (PPM), is now being tested in a first-in-human clinical trial and has shown encouraging early results for patients with non-muscle invasive bladder cancer, according to a UC Davis Health news release…